Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Risk & Volatility
Lifecore Biomedical has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Institutional and Insider Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lifecore Biomedical and InMed Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 1 | 4 | 0 | 0 | 1.80 |
| InMed Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Lifecore Biomedical presently has a consensus price target of $6.50, indicating a potential upside of 1.88%. Given Lifecore Biomedical’s stronger consensus rating and higher possible upside, equities analysts plainly believe Lifecore Biomedical is more favorable than InMed Pharmaceuticals.
Profitability
This table compares Lifecore Biomedical and InMed Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
| InMed Pharmaceuticals | N/A | -156.08% | -123.90% |
Valuation & Earnings
This table compares Lifecore Biomedical and InMed Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $128.87 million | 1.87 | -$40.50 million | ($1.07) | -5.96 |
| InMed Pharmaceuticals | $4.94 million | 0.88 | -$12.56 million | ($1.64) | -0.80 |
InMed Pharmaceuticals has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Lifecore Biomedical beats InMed Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
